These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 16173073)

  • 21. Anti-Nogo-A antibody treatment promotes recovery of manual dexterity after unilateral cervical lesion in adult primates--re-examination and extension of behavioral data.
    Freund P; Schmidlin E; Wannier T; Bloch J; Mir A; Schwab ME; Rouiller EM
    Eur J Neurosci; 2009 Mar; 29(5):983-96. PubMed ID: 19291225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury.
    Kucher K; Johns D; Maier D; Abel R; Badke A; Baron H; Thietje R; Casha S; Meindl R; Gomez-Mancilla B; Pfister C; Rupp R; Weidner N; Mir A; Schwab ME; Curt A
    Neurorehabil Neural Repair; 2018 Jun; 32(6-7):578-589. PubMed ID: 29869587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies neutralizing Nogo-A increase pan-cadherin expression and motor recovery following spinal cord injury in rats.
    Atalay B; Bavbek M; Cekinmez M; Ozen O; Nacar A; Karabay G; Gulsen S
    Spinal Cord; 2007 Dec; 45(12):780-6. PubMed ID: 17724451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repair of the injured spinal cord. A joint approach of basic and clinical research.
    Buchli AD; Rouiller E; Mueller R; Dietz V; Schwab ME
    Neurodegener Dis; 2007; 4(1):51-6. PubMed ID: 17429219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Nogo on the go: from animal models to a clinical trial.
    Zörner B; Schwab ME
    Ann N Y Acad Sci; 2010 Jun; 1198 Suppl 1():E22-34. PubMed ID: 20590535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nogo-66 receptor antagonist peptide (NEP1-40) administration promotes functional recovery and axonal growth after lateral funiculus injury in the adult rat.
    Cao Y; Shumsky JS; Sabol MA; Kushner RA; Strittmatter S; Hamers FP; Lee DH; Rabacchi SA; Murray M
    Neurorehabil Neural Repair; 2008; 22(3):262-78. PubMed ID: 18056009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-dependent beneficial and detrimental effects of ROCK inhibitor Y27632 on axonal sprouting and functional recovery after rat spinal cord injury.
    Chan CC; Khodarahmi K; Liu J; Sutherland D; Oschipok LW; Steeves JD; Tetzlaff W
    Exp Neurol; 2005 Dec; 196(2):352-64. PubMed ID: 16154567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance of interleukin-6 to the extracellular inhibitory environment promotes axonal regeneration and functional recovery following spinal cord injury.
    Yang G; Tang WY
    Int J Mol Med; 2017 Feb; 39(2):437-445. PubMed ID: 28075461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of anti-Nogo-A antibody treatment and treadmill training in rats with incomplete spinal cord injury.
    Maier IC; Ichiyama RM; Courtine G; Schnell L; Lavrov I; Edgerton VR; Schwab ME
    Brain; 2009 Jun; 132(Pt 6):1426-40. PubMed ID: 19372269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined with anti-Nogo-A antibody treatment, BDNF did not compensate the extra deleterious motor effect caused by large size cervical cord hemisection in adult macaques.
    Beaud ML; Rouiller EM; Bloch J; Mir A; Schwab ME; Schmidlin E
    CNS Neurosci Ther; 2020 Feb; 26(2):260-269. PubMed ID: 31418518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regeneration and sprouting of chronically injured corticospinal tract fibers in adult rats promoted by NT-3 and the mAb IN-1, which neutralizes myelin-associated neurite growth inhibitors.
    von Meyenburg J; Brösamle C; Metz GA; Schwab ME
    Exp Neurol; 1998 Dec; 154(2):583-94. PubMed ID: 9878193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infusion of anti-Nogo-A antibodies in adult rats increases growth and synapse related proteins in the absence of behavioral alterations.
    Craveiro LM; Weinmann O; Roschitzki B; Gonzenbach RR; Zörner B; Montani L; Yee BK; Feldon J; Willi R; Schwab ME
    Exp Neurol; 2013 Dec; 250():52-68. PubMed ID: 24076004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system.
    Buchli AD; Schwab ME
    Ann Med; 2005; 37(8):556-67. PubMed ID: 16338758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined delivery of Nogo-A antibody, neurotrophin-3 and the NMDA-NR2d subunit establishes a functional 'detour' in the hemisected spinal cord.
    Schnell L; Hunanyan AS; Bowers WJ; Horner PJ; Federoff HJ; Gullo M; Schwab ME; Mendell LM; Arvanian VL
    Eur J Neurosci; 2011 Oct; 34(8):1256-67. PubMed ID: 21995852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Nogo-A antibody treatment does not prevent cell body shrinkage in the motor cortex in adult monkeys subjected to unilateral cervical cord lesion.
    Beaud ML; Schmidlin E; Wannier T; Freund P; Bloch J; Mir A; Schwab ME; Rouiller EM
    BMC Neurosci; 2008 Jan; 9():5. PubMed ID: 18194520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of a gold nanoparticle-based adjuvant to improve the therapeutic efficacy of hNgR-Fc protein immunization in spinal cord-injured rats.
    Wang YT; Lu XM; Zhu F; Huang P; Yu Y; Zeng L; Long ZY; Wu YM
    Biomaterials; 2011 Nov; 32(31):7988-98. PubMed ID: 21784510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reorganization of descending motor tracts in the rat spinal cord.
    Raineteau O; Fouad K; Bareyre FM; Schwab ME
    Eur J Neurosci; 2002 Nov; 16(9):1761-71. PubMed ID: 12431229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nogo-A antibodies enhance axonal repair and remyelination in neuro-inflammatory and demyelinating pathology.
    Ineichen BV; Kapitza S; Bleul C; Good N; Plattner PS; Seyedsadr MS; Kaiser J; Schneider MP; Zörner B; Martin R; Linnebank M; Schwab ME
    Acta Neuropathol; 2017 Sep; 134(3):423-440. PubMed ID: 28646336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination treatment with anti-Nogo-A and chondroitinase ABC is more effective than single treatments at enhancing functional recovery after spinal cord injury.
    Zhao RR; Andrews MR; Wang D; Warren P; Gullo M; Schnell L; Schwab ME; Fawcett JW
    Eur J Neurosci; 2013 Sep; 38(6):2946-61. PubMed ID: 23790207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble cell adhesion molecule L1-Fc promotes locomotor recovery in rats after spinal cord injury.
    Roonprapunt C; Huang W; Grill R; Friedlander D; Grumet M; Chen S; Schachner M; Young W
    J Neurotrauma; 2003 Sep; 20(9):871-82. PubMed ID: 14577865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.